Firering Strategic Minerals: From explorer to producer. Watch the video here.
Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
For more information:
Tissue Regenix Group plc
David ****e, Chief Financial Officer
www.tissueregenix.com
Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)
Ben Maddison / Alex Price
Tel: +44(0)20 7710 7600
Walbrook PR Ltd
Alice Woodings / Lianne Cawthorne
Tel: +44 (0)20 7933 8780
[email protected]
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
CHAIRMAN STATEMENT
Jonathan Glenn, Chairman
Introduction
The first half of 2021 has been a period of strong recovery for the Group and one that has seen revenue growth and reduced losses, resulting in a business well-positioned for further growth as elective procedures recommence globally.
We have created a commercially focussed regenerative global medtech company in a high growth sector focused on soft tissues and bone, with a multi-billion dollar addressable market opportunity in the US alone. Our core product portfolio has two technology platforms:
· BioRinse® - natural bone filler solutions verified to be osteoinductive to stimulate and regenerate native bone growth
· dCELL® - used to produce allograft (DermaPure®) and xenograft (OrthoPure® XT) soft tissue products to promote healing and regeneration
These technologies have been used to create regenerative products with biosurgery, orthopaedics and dental applications.
Strong recovery in H1 2021
RNS Number : 0238L
Tissue Regenix Group PLC
08 September 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Half-year Report
Interim results for the six months to 30 June 2021
Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group"), the regenerative medical devices company, announces its unaudited interim results for the six months to 30 June 2021.
Financial highlights
· Group revenues increased by 12% to £6.8m (H1 2020: £6.1m, at 21% constant currency)
· Orthopaedic and Dental division recorded a 26% increase in revenues (37% constant currency) to £4.3m (H1 2020: £3.4m), driven by strong underlying performance in the US market
· Gross profit of £3.1m (H1 2020: £2.9m), delivered at a 46% gross margin (2020: 46%)
· EBITDA loss reduced 48% to £1.1m (H1 2020: £2.1m) due to sales growth and tight expense management
· Cash position of £6.6m (H1 2020: £13.7m)
Commercial highlights
· US product shipments increased by 44% in H1 2021 compared with the same period in 2020
Operational highlights
· Restructuring of US commercial operations providing savings of US c.$350k in H1 2021
· Phase one expansion of the San Antonio facility completed on time and on budget
· Both government backed loans (part of the COVID-19 relief programme) have been forgiven
· Appointment of David ****e as Chief Financial Officer
· Trevor Phillips and Brian Phillips appointed to the Board as Independent Non-Executive Directors
Post balance sheet events
· Two additional products added to the Biosurgery portfolio, DermaPure Mesh and VNEW®
Daniel Lee, Chief Executive Officer of Tissue Regenix Group plc, said: "I am proud of how the Group operated during a challenging 2020 and am encouraged by our strong H1 results, with the Group making good operational and commercial progress, as the world began its recovery from the COVID-19 pandemic.
"The additions of Brian Phillips and Trevor Phillips to the Board, as well as David ****e as CFO, have brought together a strong, commercially focussed team to drive Tissue Regenix forward as the Group builds momentum following the pandemic. I am delighted to welcome them to the Board and look forward to working with them as we broaden the Group's portfolio and increase market penetration.
"I am incredibly pleased with the progress the Group has made in H1 2021 and look forward to this being further built on in H2. We are committed to creating long-term, sustainable value for shareholders and I am greatly encouraged by this promising set of results."
Investor Presentation
Daniel Lee, Chief Executive Officer, and David ****e, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm today. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Co
Conversation
Walbrook PR
@WalbrookPR
Stifel reiterates BUY rating for Tissue Regenix
@Tissue_Regenix
#TRX: good progress towards becoming a fast-growing and profitable regenerative medicine, medical device company, reducing its cost base in order to achieve EBITDA profitability in 2H21. Target Price of 0.9p
11:38 AM · Mar 31, 2021·
RNS Number : 9452S
Omega Diagnostics Group PLC
22 March 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
CE-Mark of Mologic COVID-19 lateral flow antigen test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has CE-Marked Mologic Ltd's ('Mologic') lateral flow antigen test for COVID-19, to be sold for professional-use under Omega's VISITECT® brand. The test will provide healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.
Having commenced technology transfer late last year Omega has CE-marked the product and is now in the process of completing marketing launch for commercial roll-out which is expected to start in April. The Company is already in discussion with a number of potential commercial partners looking to order the test post launch.
The Company is well on its way to establishing a lateral flow production capacity of approximately 2 million tests per week by the end of April from its Alva facility in Scotland. This production capacity will be used to produce this VISITECT® branded antigen test for sale to third-party commercial customers.
The Company's production capacity will be used to fulfil demand across a range of lateral flow tests:
· VISITECT® CD4 Advanced Disease test - a rapid, semi-quantitative lateral flow assay used in the treatment of patients living with HIV
· VISITECT® branded COVID-19 lateral flow antigen tests - now CE marked and being launched in April as noted above
· COVID-19 Lateral flow antigen tests - under contract for the UK Government (as announced on 11 February 2021)
· VISITECT® COVID-19 IgM/IgA/IgG - a rapid test for the detection of three antibody isotypes to SARS-CoV-2
· AbC-19TM COVID-19 Rapid Antibody Test
Utilisation of the Company's weekly production capacity for the supply of antigen tests under the DHSC contract, and the supply of the other tests above, is expected to have a significant impact on the future performance of the business and whilst volumes are unquantified it is likely to result in substantial revenue growth in the financial year beginning 1 April 2021.
Colin King, CEO of Omega, commented: "This is an exciting and important next step in our COVID strategy as we now have the ability to supply both antigen and antibody lateral flow tests not only to the UK Government but also to our commercial partners. Having both tests available and having built our production capacity allows us to adjust our capacity to meet the demands of the pandemic. We look forward with confidence that the coming year ahead will be truly transformational for Omega."
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Screen4 Ltd
@Screen4org
· 18h
Have you had Covid19? Have you had the Covid19 Vaccine?
Our new Home Use Antibody test can help you to identify the level of antibodies your immune system has built
Find out more: https://screen4.org/product/finger-prick-antibody-test/…
#COVID19 #omegadiagnostics #antibodytest #vaccine
£52.00 Each
https://screen4.org/product/finger-prick-antibody-test/…
Great news this evening following a great article from
@paulwaugh
in the
@HuffPost
.
Quality LFTs via the UK-RATC are the answer to normality resuming Flag of United Kingdom
Make no bones about it,
@OmegaDiagnostic
are now part of an industry worth multiple billions.
https://m.huffingtonpost.co.uk/amp/entry/five
RNS Number : 2330O
Omega Diagnostics Group PLC
08 February 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Statement re. media comment
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the article published online yesterday by the Financial Times.
The Company can confirm that it is continuing to modify its Alva-based facility to upscale significantly its lateral flow test production capacity. When contracts or supply agreements are signed to utilise this capacity the Company will announce this in line with AIM disclosure obligations.
Contacts:
Omega Diagnostics Group PLC
Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd
Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited
Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07584 391 303